L&C BIOLTD Past Earnings Performance
Past criteria checks 5/6
L&C BIOLTD has been growing earnings at an average annual rate of 50.4%, while the Biotechs industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 19.7% per year. L&C BIOLTD's return on equity is 48.6%, and it has net margins of 198.8%.
Key information
50.37%
Earnings growth rate
49.73%
EPS growth rate
| Biotechs Industry Growth | 11.70% |
| Revenue growth rate | 19.75% |
| Return on equity | 48.60% |
| Net Margin | 198.82% |
| Last Earnings Update | 31 Dec 2024 |
Recent past performance updates
L&C BIOLTD's (KOSDAQ:290650) Performance Raises Some Questions
Apr 01
L&C Bio's (KOSDAQ:290650) Performance Raises Some Questions
Mar 27L&C Bio's (KOSDAQ:290650) Earnings Are Of Questionable Quality
Apr 01Recent updates
L&C BIOLTD's (KOSDAQ:290650) Performance Raises Some Questions
Apr 01There's No Escaping L&C BIO Co.,LTD's (KOSDAQ:290650) Muted Revenues Despite A 30% Share Price Rise
Dec 14Is L&C BIOLTD (KOSDAQ:290650) A Risky Investment?
Nov 12Here's Why L&C BIOLTD (KOSDAQ:290650) Has A Meaningful Debt Burden
Aug 06What L&C BIO Co.,LTD's (KOSDAQ:290650) 27% Share Price Gain Is Not Telling You
Jul 05L&C Bio's (KOSDAQ:290650) Performance Raises Some Questions
Mar 27Does L&C Bio (KOSDAQ:290650) Deserve A Spot On Your Watchlist?
Apr 20L&C Bio's (KOSDAQ:290650) Earnings Are Of Questionable Quality
Apr 01Is L&C Bio (KOSDAQ:290650) A Risky Investment?
Mar 02Announcing: L&C Bio (KOSDAQ:290650) Stock Increased An Energizing 163% In The Last Year
Feb 03What Is The Ownership Structure Like For L&C Bio Co., Ltd (KOSDAQ:290650)?
Jan 04Should You Be Excited About L&C Bio Co., Ltd's (KOSDAQ:290650) 16% Return On Equity?
Dec 08Revenue & Expenses Breakdown
How L&C BIOLTD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 24 | 72,093 | 143,336 | 25,863 | 4,907 |
| 30 Sep 24 | 70,031 | -5,961 | 24,815 | 4,190 |
| 30 Jun 24 | 72,043 | 49,008 | 22,935 | 4,190 |
| 31 Mar 24 | 70,635 | 49,313 | 21,878 | 3,946 |
| 31 Dec 23 | 65,927 | 48,689 | 20,476 | 3,152 |
| 30 Sep 23 | 67,487 | 53,593 | 18,332 | 2,823 |
| 30 Jun 23 | 59,716 | 4,114 | 15,693 | 2,823 |
| 31 Mar 23 | 56,370 | 3,882 | 15,784 | 1,417 |
| 31 Dec 22 | 52,572 | 4,544 | 13,941 | 2,195 |
| 30 Sep 22 | 50,399 | 11,092 | 13,382 | 2,728 |
| 30 Jun 22 | 49,553 | 12,530 | 13,076 | 2,728 |
| 31 Mar 22 | 47,101 | 13,176 | 11,602 | 2,786 |
| 31 Dec 21 | 45,677 | 13,814 | 12,057 | 2,295 |
| 30 Sep 21 | 41,579 | 11,021 | 12,236 | 2,445 |
| 30 Jun 21 | 37,956 | 11,146 | 10,696 | 2,445 |
| 31 Mar 21 | 35,141 | 11,107 | 10,908 | 2,448 |
| 31 Dec 20 | 32,973 | 10,813 | 9,555 | 2,381 |
| 30 Sep 20 | 31,868 | 7,213 | 8,310 | 1,792 |
| 30 Jun 20 | 30,410 | 6,978 | 8,133 | 1,792 |
| 31 Mar 20 | 30,333 | 7,288 | 7,952 | 1,672 |
| 31 Dec 19 | 29,152 | 7,250 | 8,023 | 1,346 |
| 30 Sep 19 | 27,348 | 6,505 | 7,901 | 1,554 |
| 30 Jun 19 | 24,978 | 5,860 | 7,313 | 1,554 |
| 31 Mar 19 | 22,624 | 5,521 | 6,946 | 1,421 |
| 31 Dec 18 | 21,241 | 5,208 | 6,543 | 1,268 |
| 30 Sep 18 | 19,618 | 5,186 | 5,715 | 1,020 |
| 30 Jun 18 | 19,966 | 5,396 | 5,101 | 1,218 |
| 31 Mar 18 | 18,631 | 4,345 | 4,821 | 1,244 |
| 31 Dec 17 | 17,901 | 3,753 | 5,263 | 918 |
Quality Earnings: A290650 has a high level of non-cash earnings.
Growing Profit Margin: A290650's current net profit margins are higher than last year (73.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A290650's earnings have grown significantly by 50.4% per year over the past 5 years.
Accelerating Growth: A290650's earnings growth over the past year (194.4%) exceeds its 5-year average (50.4% per year).
Earnings vs Industry: A290650 earnings growth over the past year (194.4%) exceeded the Biotechs industry 64.9%.
Return on Equity
High ROE: A290650's Return on Equity (48.6%) is considered outstanding.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/28 16:51 |
| End of Day Share Price | 2025/05/28 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
L&C BIO Co.,LTD is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyung-rae Han | Daishin Securities Co. Ltd. |
| Jongsun Park | Eugene Investment & Securities Co Ltd. |
| Min-jung Kwag | Hyundai Motor Securities Co. Ltd. |